GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes By Ogkologos - July 13, 2026 79 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large real-world cohort Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... April 20, 2023 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma April 1, 2026 FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment July 7, 2020 Load more HOT NEWS Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... MAP Congress 2020: Molecular Analysis for Precision Oncology ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive...
